#Canada #Concord #minoxidil #Glenmark #Hair Regrowth

Glenmark Pharmaceuticals Canada Inc. Unveils Men’s GLN-Minoxidil 5% w/w Topical Aerosol Foam

In a significant move aimed at addressing men's hair loss issues, Glenmark Pharmaceuticals Canada Inc. has officially launched its latest product, Men's GLN-Minoxidil 5% w/w (50 mg/g) Topical Aerosol Foam. This innovative solution is expected to make waves in the Canadian retail market, catering to a growing demand for effective hair regrowth treatments among men and expanding the company's over-the-counter (OTC) portfolio.

Expanding Access to Hair Loss Treatments

Men’s GLN-Minoxidil Foam is formulated with 5% minoxidil, a clinically recognized and practical ingredient known for promoting hair regrowth. The product features a fast-drying, unscented aerosol that allows for a precise application without the mess commonly associated with liquid treatments. Its no-drip formula facilitates easy and efficient use, which can enhance adoption rates among users. With affordability and convenience at its core, Glenmark aims to reduce barriers associated with consistent treatment, ultimately improving access to this solution for those battling hair loss.

Early Success in E-Commerce

Even before its broader retail release, GLN-Minoxidil Men's 5% Foam has shown promising performance in Canadian e-commerce channels. The product has quickly gained traction, ranking among the top-selling hair regrowth treatments on Amazon.ca, primarily due to its combination of effective results and positive consumer feedback. This early success serves as a testament to the product's potential in meeting the needs of men seeking viable solutions for hair loss.

Commitment to Quality and Accessibility

Marc Kikuchi, President and Business Head for North America at Glenmark, highlighted the firm's dedication to meeting evolving patient needs. He remarked, "At Glenmark, our focus is on expanding access to high-quality, reliable treatment options that meet evolving patients' needs. The launch of GLN Minoxidil Men's 5% Foam reflects our commitment to building a differentiated OTC portfolio by combining efficacy with convenience and affordability."

As Glenmark continues to build its OTC business, consistent growth over the past five years reaffirms the company’s strategy to provide branded, accessible treatment options. This latest launch aligns with their vision of enhancing the health and well-being of men while addressing important societal issues such as hair loss.

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. is recognized as a global leader in the pharmaceutical sector, boasting a strong focus on innovation and research. The company is dedicated to pioneering transformative therapies, forging a path toward more effective and accessible treatment options worldwide. Glenmark operates 11 advanced manufacturing facilities and six research and development centers across four continents while maintaining a wide commercial presence in over 80 countries. This commitment to providing diverse products ranges from branded medications to generics and consumer health items, with particular expertise in areas such as respiratory, dermatology, and oncology.

Glenmark’s emphasis on research and customer-centric solutions solidifies its reputation as one of the top biopharmaceutical companies worldwide, as recognized by Scrip 100 for 2024. For more information, visit www.glenmarkpharma.com.